UY32664A - Nuevas inmunoglobulinas que se enlazan con interleuquinas - Google Patents

Nuevas inmunoglobulinas que se enlazan con interleuquinas

Info

Publication number
UY32664A
UY32664A UY0001032664A UY32664A UY32664A UY 32664 A UY32664 A UY 32664A UY 0001032664 A UY0001032664 A UY 0001032664A UY 32664 A UY32664 A UY 32664A UY 32664 A UY32664 A UY 32664A
Authority
UY
Uruguay
Prior art keywords
interleuquins
link
immunoglobulins
new
new immunoglobulins
Prior art date
Application number
UY0001032664A
Other languages
English (en)
Spanish (es)
Inventor
Paul Andrew Hamblin
Alan Peter Lewis
Ashman Claire
Ellis Jonathan Henry
Martin Anibal Orecchia
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY32664A publication Critical patent/UY32664A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UY0001032664A 2009-05-28 2010-05-26 Nuevas inmunoglobulinas que se enlazan con interleuquinas UY32664A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18183309P 2009-05-28 2009-05-28
US28893009P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
UY32664A true UY32664A (es) 2010-12-31

Family

ID=42335086

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032664A UY32664A (es) 2009-05-28 2010-05-26 Nuevas inmunoglobulinas que se enlazan con interleuquinas

Country Status (21)

Country Link
US (2) US20100303821A1 (cg-RX-API-DMAC7.html)
EP (1) EP2435481A1 (cg-RX-API-DMAC7.html)
JP (1) JP5919188B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120034679A (cg-RX-API-DMAC7.html)
CN (1) CN102459341A (cg-RX-API-DMAC7.html)
AR (1) AR078047A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010251955A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1016061A2 (cg-RX-API-DMAC7.html)
CA (1) CA2763443A1 (cg-RX-API-DMAC7.html)
CO (1) CO6400150A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110664A (cg-RX-API-DMAC7.html)
DO (1) DOP2011000347A (cg-RX-API-DMAC7.html)
EA (1) EA201190275A1 (cg-RX-API-DMAC7.html)
IL (1) IL216261A0 (cg-RX-API-DMAC7.html)
MA (1) MA33381B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011012622A (cg-RX-API-DMAC7.html)
PE (1) PE20120401A1 (cg-RX-API-DMAC7.html)
SG (1) SG176203A1 (cg-RX-API-DMAC7.html)
TW (1) TW201107345A (cg-RX-API-DMAC7.html)
UY (1) UY32664A (cg-RX-API-DMAC7.html)
WO (1) WO2010136481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
CA2763443A1 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Il-13 binding protein
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CN113156139A (zh) * 2013-01-03 2021-07-23 梅索磅秤技术有限公司 测定实验对象组
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10035823B2 (en) 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
AU2016304764C1 (en) 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
KR20180073561A (ko) * 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CN118005784A (zh) * 2022-11-08 2024-05-10 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
JP2005525404A (ja) 2002-05-01 2005-08-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｉｖ感染およびａｉｄｓを処置するためにサイトカインアンタゴニストを使用する方法
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
CA2636854A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
EP1976991A1 (en) * 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
AR069495A1 (es) 2007-11-30 2010-01-27 Glaxo Group Ltd Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
MX348362B (es) 2008-03-31 2017-06-07 Genentech Inc * Composiciones y metodos para tratar y diagnosticar asma.
CA2763443A1 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Il-13 binding protein

Also Published As

Publication number Publication date
TW201107345A (en) 2011-03-01
CA2763443A1 (en) 2010-12-02
DOP2011000347A (es) 2012-01-15
US20120082682A1 (en) 2012-04-05
EA201190275A1 (ru) 2012-11-30
US20100303821A1 (en) 2010-12-02
CR20110664A (es) 2012-02-27
WO2010136481A1 (en) 2010-12-02
PE20120401A1 (es) 2012-05-04
BRPI1016061A2 (pt) 2016-09-13
SG176203A1 (en) 2011-12-29
EP2435481A1 (en) 2012-04-04
MA33381B1 (fr) 2012-06-01
MX2011012622A (es) 2011-12-14
US8680245B2 (en) 2014-03-25
AR078047A1 (es) 2011-10-12
IL216261A0 (en) 2012-01-31
KR20120034679A (ko) 2012-04-12
CN102459341A (zh) 2012-05-16
JP2012528110A (ja) 2012-11-12
CO6400150A2 (es) 2012-03-15
JP5919188B2 (ja) 2016-05-18
AU2010251955A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
UY32664A (es) Nuevas inmunoglobulinas que se enlazan con interleuquinas
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1119055T1 (el) Αντισωματα που προσδενονται στην il-17a και στην il-17f
EA201492149A8 (ru) St2-антигенсвязывающие белки
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
UY33421A (es) Proteinas de union al antígeno humanizados
CR20150101A (es) Anticuerpos que se unen a il-4 y/o il-13
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
CR20110152A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
HUE053489T2 (hu) Az anti-il-13 antitestek izolálása és tisztítása a protein A affinitás kromatográviával
ECSP12011879A (es) Anticuerpo anti-tslp modificado por técnicas de ingeniería genética
MX357678B (es) Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43).
EA201690803A1 (ru) Получение переориентирующих т-клетки гетеродимерных иммуноглобулинов
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
UA123202C2 (uk) Антитіло до тау-білка і його застосування
CO6400149A2 (es) Proteínas de enlace a miostatina
MX2011010707A (es) Anticuerpos dkk-1.
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
CR20150161A (es) Proteínas ligantes de antígeno her3 de unión a la horquilla beta de her3
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
ECSP12012202A (es) Anticuerpos il-25 humanizados
ECSP11011429A (es) Tratamiento de trastornos resistentes a insulina